Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74

Amphastar Pharmaceuticals, Inc.

2025-FY EPS reported $2.03 revenue$719,887,000

Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.
GAAP net income Q4 $24.4M ($0.51 diluted EPS) vs $38.0M ($0.74) in Q4 2024; FY $98.1M ($2.03) vs $159.5M ($3.06).
Adjusted non-GAAP net income Q4 $34.2M ($0.73 diluted EPS) vs $47.2M ($0.92) a year ago.
CEO cites BAQSIMI double-digit growth and FDA approvals of iron sucrose and teriparatide injections as positives.
Three novel peptides and a synthetic corticotropin compound added to pipeline for oncology, ophthalmology, and immunology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.